Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 184
Filter
1.
Clin Immunol ; 257: 109837, 2023 12.
Article in English | MEDLINE | ID: mdl-37944684

ABSTRACT

Telomere biology disorders (TBD) are caused by germline pathogenic variants in genes related to telomere maintenance and are characterized by critically short telomeres. In contrast to classical dyskeratosis congenita (DC), which is typically diagnosed in infancy, adult or late onset TBD frequently lack the typical DC triad and rather show variable organ manifestations and a cryptic disease course, thus complicating its diagnosis. Common variable immunodeficiency (CVID), on the other hand, is a primary antibody deficiency (PAD) syndrome. PADs are a heterogenous group of diseases characterized by hypogammaglobulinemia which occurs due to dysfunctional B lymphocytes and additional autoimmune and autoinflammatory complications. Genetic screening reveals a monogenic cause in a subset of CVID patients (15-35%). In our study, we screened the exomes of 491 CVID patients for the occurrence of TBD-related variants in 13 genes encoding for telomere/telomerase-associated proteins, which had previously been linked to the disease. We found 110/491 patients (22%) carrying 91 rare candidate variants in these 13 genes. Following the American College of Medical Genetics and Genomics (ACMG) guidelines, we classified two variants as benign, two as likely benign, 64 as variants of uncertain significance (VUS), four as likely pathogenic, and one heterozygous variant in an autosomal recessive disease gene as pathogenic. We performed telomere length measurement in 42 of the 110 patients with candidate variants and CVID. Two of these 42 patients showed significantly shorter telomeres compared to controls in both lymphocytes and granulocytes. Following the evaluation of the published literature and the patient's manifestations, we re-classified two VUS as likely pathogenic variants. Thus, 0.5-1% of all CVID patients in our study carry possibly pathogenic variants in telomere/telomerase-associated genes. Our data adds CVID to the broad clinical spectrum of cryptic adult-onset TBD. As the molecular diagnosis greatly impacts patient management and treatment strategies, we advise inclusion of all TBD-associated genes-despite their low prevalence-into the molecular screening of patients with antibody deficiencies.


Subject(s)
Common Variable Immunodeficiency , Dyskeratosis Congenita , Primary Immunodeficiency Diseases , Telomerase , Adult , Humans , Common Variable Immunodeficiency/genetics , Telomerase/genetics , Telomerase/metabolism , Telomere/genetics , Telomere/metabolism , Telomere/pathology , Dyskeratosis Congenita/genetics , Dyskeratosis Congenita/diagnosis , Dyskeratosis Congenita/pathology , Biology
4.
Exp Clin Transplant ; 21(4): 368-374, 2023 04.
Article in English | MEDLINE | ID: mdl-28969530

ABSTRACT

Dyskeratosis congenita is a rare congenital telomeropathy characterized by cutaneous and nail dystrophy, oral leukoplakia, and bone marrow failure. Pulmonary fibrosis and cancers are late manifestations. Allogeneic hematopoietic stem cell transplant represents the only cure for those with bone marrow failure with this disease, but outcomes reported are overall poor, with organ toxicities, graft failure, and graft-versus-host disease as main issues. Although reduced intensity conditioning regimens seem to be related to better outcomes, a standard regimen for dyskeratosis congenita has never been defined. Here, we report a successful long-term outcome of an 8-year-old girl with dyskeratosis congenita who received 2 consecutive allogeneic hematopoietic stem cell transplants from different unrelated donors, because of rejection after the first one, both conditioned with fludarabine-based reduced intensity conditioning regimen. The second transplant was complicated by severe hemorrhagic cystitis and acute grade IV graft-versus-host disease in the early phase and mild chronic graft-versus-host disease and ureteral stenosis in the late phase. This experience confirms that dyskeratosis congenita is at high risk for transplant-related morbidity but that a fludarabine-based reduced intensity conditioning regimen is a safe and feasible option as a preparative regimen, as shown here in a second transplant after first graft rejection. To reduce the risk of graft-versus-host disease, more effective prophylaxis schedules should be chosen in cases of unrelated donor, and haploidentical hematopoietic stem cell transplant with in vitro α/ ß + and CD19+ depletion should be considered.


Subject(s)
Dyskeratosis Congenita , Graft vs Host Disease , Hematopoietic Stem Cell Transplantation , Female , Humans , Child , Graft Rejection/prevention & control , Unrelated Donors , Dyskeratosis Congenita/diagnosis , Dyskeratosis Congenita/surgery , Dyskeratosis Congenita/complications , Transplantation Conditioning/adverse effects , Hematopoietic Stem Cell Transplantation/adverse effects , Graft vs Host Disease/diagnosis , Graft vs Host Disease/etiology , Graft vs Host Disease/prevention & control
6.
Eur J Ophthalmol ; 33(3): NP122-NP125, 2023 May.
Article in English | MEDLINE | ID: mdl-35243907

ABSTRACT

PURPOSE: To describe a young male with bilateral sequential Cytomegalovirus retinitis (CMVR) as the presenting feature of Dyskeratosis Congenita. CASE REPORT: A 25-year-old human immunodeficiency virus (HIV) negative male developed CMVR in his left eye, while on a three week course of oral valganciclovir therapy for CMV retinitis in his right eye. Systemic examination revealed reticular hypopigmentation of the forearms, dystrophic nails, oral leukoplakia and complete blood counts showed pancytopenia. A diagnosis of Dyskeratosis Congenita was confirmed with genetic testing. CONCLUSION: CMVR in non-HIV individuals should be considered as a harbinger of systemic immunosuppressive conditions. Ophthalmologists may be the first ones to suspect and diagnose congenital immunosuppressive disorders like Dyskeratosis Congenita in these patients.


Subject(s)
Cytomegalovirus Retinitis , Dyskeratosis Congenita , Humans , Male , Adult , Cytomegalovirus Retinitis/diagnosis , Cytomegalovirus Retinitis/drug therapy , Cytomegalovirus/genetics , Dyskeratosis Congenita/complications , Dyskeratosis Congenita/diagnosis , Dyskeratosis Congenita/drug therapy , Valganciclovir , Eye , Immunosuppressive Agents
7.
Hematology ; 27(1): 1041-1045, 2022 Dec.
Article in English | MEDLINE | ID: mdl-36073719

ABSTRACT

OBJECTIVES: Dyskeratosis congenita (DC) is a rare inherited disease characterized by the triad of reticulate hyperpigmentation, nail dystrophy and oral leukoplakia. DC patients are considered vulnerable to external pressure, such as immunochemotherapy. There are very few cases reporting severe therapy-induced toxicities in patients with DC. METHODS: A 27-year-old woman was admitted to our hospital with a 4-month history of pancytopenia and a 7-day history of dyspnea with coughing. She was diagnosed with non-Hodgkin's lymphoma 5 months ago. She received immunochemotherapy due to non-Hodgkin's lymphoma but experienced recurrent fever, oral ulcer, pancytopenia, dyspnea and other symptoms during immunochemotherapy. On admission, she experienced an aggravation of respiratory symptoms, recurrent infections and acute heart failure. RESULTS: Laboratory examination confirmed pancytopenia, and chest computed tomography showed interstitial lung disease (ILD). Genetic analysis results confirmed the presence of DC and a TINF2 gene mutation. With continuous supportive and anti-infection treatment, her condition finally stabilized. She was discharged from the hospital after nearly 2 months. DISCUSSION: We reviewed similar cases and found common features that could be useful. However, the reported cases are very limited. More cases and studies are needed. CONCLUSION: These cases indicate that DC patients seem more vulnerable to therapy toxicities; thus, physicians should be careful when treating these patients with chemotherapy drugs or radiation therapy. Reduced-intensity therapy may be considered.


Subject(s)
Dyskeratosis Congenita , Lymphoma, Non-Hodgkin , Pancytopenia , Adult , Dyskeratosis Congenita/complications , Dyskeratosis Congenita/diagnosis , Dyskeratosis Congenita/therapy , Dyspnea , Female , Humans , Leukoplakia, Oral , Pancytopenia/chemically induced
8.
Expert Rev Hematol ; 15(8): 685-696, 2022 08.
Article in English | MEDLINE | ID: mdl-35929966

ABSTRACT

BACKGROUND: Dyskeratosis congenita (DC) is a multisystem syndrome characterized by mucocutaneous abnormalities, bone marrow failure, and predisposition to cancer. Studies over the last 25 years have led to the identification of 18 disease genes. These have a principal role in telomere maintenance, and patients usually have very short/abnormal telomeres. The advances have also led to the unification of DC with a number of other diseases, now collectively referred to as the telomeropathies or telomere biology disorders. WHAT IS COVERED: Clinical features, genetics, and biology of the different subtypes. Expert view on diagnosis, treatment of the hematological complications and future. EXPERT VIEW: As these are very pleotropic disorders affecting multiple organs, a high index of suspicion is necessary to make the diagnosis. Telomere length measurement and genetic analysis of the disease genes have become useful diagnostic tools. Although hematological defects can respond to danazol/oxymetholone, the only current curative treatment for these is hematopoietic stem cell transplantation (HSCT) using fludarabine-based conditioning protocols. New therapies are needed where danazol/oxymetholone is ineffective and HSCT is not feasible.


Subject(s)
Dyskeratosis Congenita , Telomerase , Biology , Danazol , Dyskeratosis Congenita/diagnosis , Dyskeratosis Congenita/genetics , Dyskeratosis Congenita/therapy , Humans , Mutation , Oxymetholone , Telomere/genetics , Telomere/metabolism
11.
Genes (Basel) ; 13(3)2022 03 11.
Article in English | MEDLINE | ID: mdl-35328050

ABSTRACT

Dyskeratosis congenital (DC) is the first genetic syndrome described among telomeropathies. Its classical phenotype is characterized by the mucocutaneous triad of reticulated pigmentation of skin lace, nail dystrophy and oral leukoplakia. The clinical presentation, however, is heterogeneous and serious clinical complications include bone marrow failure, hematological and solid tumors. It may also involve immunodeficiencies, dental, pulmonary and liver disorders, and other minor complication. Dyskeratosis congenita shows marked genetic heterogeneity, as at least 14 genes are responsible for the shortening of telomeres characteristic of this disease. This review discusses clinical characteristics, molecular genetics, disease evolution, available therapeutic options and differential diagnosis of dyskeratosis congenita to provide an interdisciplinary and personalized medical assessment that includes family genetic counseling.


Subject(s)
Dyskeratosis Congenita , Nails, Malformed , Dyskeratosis Congenita/diagnosis , Dyskeratosis Congenita/genetics , Dyskeratosis Congenita/pathology , Humans , Leukoplakia, Oral/complications , Leukoplakia, Oral/pathology , Rare Diseases/diagnosis , Rare Diseases/genetics , Telomere
13.
Life Sci Alliance ; 5(1)2022 01.
Article in English | MEDLINE | ID: mdl-34645668

ABSTRACT

Telomerase extends chromosome ends in somatic and germline stem cells to ensure continued proliferation. Mutations in genes critical for telomerase function result in telomeropathies such as dyskeratosis congenita, frequently resulting in spontaneous bone marrow failure. A dyskeratosis congenita mutation in TPP1 (K170∆) that specifically compromises telomerase recruitment to telomeres is a valuable tool to evaluate telomerase-dependent telomere length maintenance in mice. We used CRISPR-Cas9 to generate a mouse knocked in for the equivalent of the TPP1 K170∆ mutation (TPP1 K82∆) and investigated both its hematopoietic and germline compartments in unprecedented detail. TPP1 K82∆ caused progressive telomere erosion with increasing generation number but did not induce steady-state hematopoietic defects. Strikingly, K82∆ caused mouse infertility, consistent with gross morphological defects in the testis and sperm, the appearance of dysfunctional seminiferous tubules, and a decrease in germ cells. Intriguingly, both TPP1 K82∆ mice and previously characterized telomerase knockout mice show no spontaneous bone marrow failure but rather succumb to infertility at steady-state. We speculate that telomere length maintenance contributes differently to the evolutionary fitness of humans and mice.


Subject(s)
Dyskeratosis Congenita/diagnosis , Dyskeratosis Congenita/genetics , Germ Cells/metabolism , Hematopoiesis/genetics , Mutation , Telomere-Binding Proteins/genetics , Amino Acid Sequence , Animals , CRISPR-Cas Systems , Fertility/genetics , Gene Editing , Homozygote , Humans , Lymphopoiesis/genetics , Male , Mice , Mice, Knockout , Models, Molecular , Organ Specificity/genetics , Organ Specificity/immunology , Sperm Count , Structure-Activity Relationship
14.
Exp Clin Transplant ; 20(7): 702-705, 2022 07.
Article in English | MEDLINE | ID: mdl-33272154

ABSTRACT

Dyskeratosis congenita, a rare genetic disorder typified by progressive bone marrow failure, is classically characterized by the triad of abnormal skin pigmentation, nail dystrophy, and oral leukoplakia; however, it is a multisystem disease. Although hepatic involvement occurs in about 7% of patients with dyskeratosis congenita, end-stage liver disease is rare. Treatment of dyskeratosis congenita generally involves hematopoietic stem cell transplant. For patients with hepatic failure, liver transplant can be an option. Here, we describe a case of a patient with dyskeratosis congenita who presented with liver failure and pulmonary failure, precluding him from hematopoietic stem cell transplant. After liver transplant, the patient had significant improvements in pulmonary function and transfusion requirements, allowing the patient to qualify for hematopoietic stem cell transplant. Although hematopoietic stem cell transplant is typically the first step in the management of dyskeratosis congenita, for patients with severe hepatic manifestations of the disease, a liver transplant first approach may result in better disease management.


Subject(s)
Dyskeratosis Congenita , Liver Transplantation , Dyskeratosis Congenita/complications , Dyskeratosis Congenita/diagnosis , Dyskeratosis Congenita/genetics , Humans , Leukoplakia, Oral/complications , Liver , Liver Transplantation/adverse effects , Male , Treatment Outcome
15.
Am J Med Genet A ; 188(4): 1226-1232, 2022 04.
Article in English | MEDLINE | ID: mdl-34890115

ABSTRACT

Short telomere syndromes constitute a heterogeneous group of clinical conditions characterized by short telomeres and impaired telomerase activity due to pathogenic variants in the essential telomerase components. Dyskeratosis congenita (DC) is a rare, multisystemic telomere biology disorder characterized by abnormal skin pigmentation, oral leukoplakia and nail dysplasia along with various somatic findings. Hoyeraal-Hreidarsson syndrome (HHS) is generally an autosomal recessively inherited subgroup showing growth retardation, microcephaly, cerebellar hypoplasia and severe immunodeficiency. We here report on a consanguineous family from Turkey, in which a missense variant in the reverse transcriptase domain of the TERT gene segregated with short telomere lengths and was associated with full-blown short telomere syndrome phenotype in the index; and heterogeneous adult-onset manifestations in heterozygous individuals.


Subject(s)
Dyskeratosis Congenita , Intellectual Disability , Microcephaly , Telomerase , Dyskeratosis Congenita/diagnosis , Dyskeratosis Congenita/genetics , Dyskeratosis Congenita/pathology , Fetal Growth Retardation , Humans , Intellectual Disability/genetics , Microcephaly/diagnosis , Microcephaly/genetics , Microcephaly/pathology , Mutation , Telomerase/genetics , Telomerase/metabolism , Telomere/genetics
16.
Int J Surg Pathol ; 30(3): 350-355, 2022 May.
Article in English | MEDLINE | ID: mdl-34714693

ABSTRACT

Short telomere syndrome (STS) encompasses a broad family of genetically inherited conditions caused by various mutations in telomerase and other telomere maintenance genes, resulting in premature telomere shortening. STS involves a variety of clinical manifestations, including dyskeratosis congenita, premature achromotrichia, bone marrow failure, immunodeficiency, pulmonary fibrosis and liver disease. Liver histopathologic features in STS patients have not been well characterized. We report a 46-year-old male patient who presented for dyspnea. The patient had a complicated medical history significant for immune thrombocytopenic purpura and splenectomy, recurrent respiratory tract infections, pneumonia, primary immunodeficiency, and severe hepatopulmonary syndrome. He and his brother both developed gray hair by their late 20s. He had a long history of intermittently elevated liver enzymes starting at age 33. These clinical manifestations prompted an evaluation for a possible telomere biology disorder, which revealed the telomere length was critically short and fell at or below the first percentile for age, supporting the diagnosis. The liver biopsy showed marked portal inflammation with interface hepatitis, ductular reaction and frequent foci of lobular inflammation with focal hepatocyte dropout. Hepatocytes around the portal tracts demonstrated ballooning degeneration and occasional Mallory-Denk bodies. A trichrome stain highlighted bridging fibrosis. A literature review shows liver histology is available in only a small number of STS patients, demonstrating a variety of morphologic features. Our case and others suggest liver disease associated with STS exhibits a spectrum of histopathology. Being aware of these features is important for establishing the correct diagnosis of STS which is under recognized.


Subject(s)
Dyskeratosis Congenita , Liver Diseases , Adult , Dyskeratosis Congenita/diagnosis , Dyskeratosis Congenita/genetics , Dyskeratosis Congenita/pathology , Growth Disorders , Humans , Hypercalcemia , Inflammation , Liver Diseases/diagnosis , Liver Diseases/genetics , Male , Metabolic Diseases , Middle Aged , Mutation , Nephrocalcinosis , Telomere/genetics , Telomere/pathology
17.
Medicina (B Aires) ; 81(5): 850-852, 2021.
Article in English | MEDLINE | ID: mdl-34633962

ABSTRACT

Dyskeratosis congenita is a rare inheritable disease which causes peculiar dermatological features and bone marrow failure with an increased risk of severe infections and neoplasia. Actinomyces spp. is part of the oral cavity flora. Invasive infections are mostly seen in immunocompromised hosts. We report a case of a rare central nervous infection and an underling inheritable disease.


La disqueratosis congénita es una enfermedad hereditaria, caracterizada por alteraciones cutáneas y aplasia medular. La principal causa de muerte son las infecciones y el desarrollo de neoplasias. Actinomices spp. son patógenos comensales de la cavidad oral y el tracto urinario, que en raras ocasiones suelen causar infecciones invasivas en el ser humano. Suelen ser más frecuentes en pacientes inmunocomprometidos o con mala higiene dental. Presentamos el caso de una lesión ocupante de espacio a nivel del sistema nervioso central con una inmunodeficiencia heredable.


Subject(s)
Brain Abscess , Dyskeratosis Congenita , Brain Abscess/diagnostic imaging , Dyskeratosis Congenita/complications , Dyskeratosis Congenita/diagnosis , Humans
18.
Medicina (B.Aires) ; 81(5): 850-852, oct. 2021. graf
Article in English | LILACS | ID: biblio-1351060

ABSTRACT

Abstract Dyskeratosis congenita is a rare inheritable disease which causes peculiar dermatological features and bone marrow failure with an increased risk of severe infections and neoplasia. Actinomyces spp. is part of the oral cavity flora. Invasive infections are mostly seen in immunocompromised hosts. We report a case of a rare central nervous infection and an underling inheritable disease.


Resumen La disqueratosis congénita es una enfermedad hereditaria, caracterizada por alteraciones cutáneas y aplasia medular. La principal causa de muerte son las infecciones y el desarrollo de neoplasias. Actinomices spp. son patógenos comensales de la cavidad oral y el tracto urinario, que en raras ocasiones suelen causar infecciones invasivas en el ser humano. Suelen ser más frecuentes en pacientes inmunocomprometidos o con mala higiene dental. Presentamos el caso de una lesión ocupante de espacio a nivel del sistema nervioso central con una inmuno deficiencia heredable.


Subject(s)
Humans , Brain Abscess/diagnostic imaging , Dyskeratosis Congenita/complications , Dyskeratosis Congenita/diagnosis
19.
BMC Pulm Med ; 21(1): 279, 2021 Sep 03.
Article in English | MEDLINE | ID: mdl-34479523

ABSTRACT

BACKGROUND: Dyskeratosis congenita (DC) is a rare genetic disorder of poor telomere maintenance. Pulmonary fibrosis (PF) related to DC is rarely reported. CASE PRESENTATION: A 23-year-old student presented with a four-year history of progressive cough and exertional dyspnea. Physical examination was remarkable for typical mucocutaneous abnormalities. Chest computerized tomography scan revealed interstitial fibrosis. Testing of peripheral blood leukocytes confirmed that his telomeres were 30th percentile of age-matched controls. A heterozygous missense mutation located in exon 22 of PARN gene was identified in the patient by whole exome sequencing. The patient refused danazol therapy and lung transplantation, and died of respiratory failure 2 years later. In addition, this case and 26 reported cases of DC-related PF identified through the comprehensive search of PubMed, Web of Science, WANFANG and CNKI were reviewed. Later-onset PF was observed in 11 patients (40.7%). Radiological usual interstitial pneumonia (UIP) pattern or possible UIP pattern was noted only in half of patients. However, histopathological UIP or probable UIP patterns were found in 63.6% of patients. Age at bone marrow failure (BMF) and the frequency of normal to mild thrombocytopenia in later-onset patients was significantly higher than in early-onset patients (p = 0.017 and p = 0.021, respectively). Age at PF and age at BMF in DC patients with TERC/TERT variants was significantly higher than in those with TINF2 variants or DKC1/NHP2 variants (p = 0.004 and p = 0.003, respectively). The patients with TERT/TERC/RTEL1/PARN variants had a significantly better transplant-free survival than those with TINF2 variants or DKC1/NHP2 variants (p < 0.05). Patients who underwent surgical lung biopsy had significantly worse transplant-free survival than those without lung biopsy (p = 0.042). Worse survival was found in patients with immunosuppression therapy than in those without (p = 0.012). CONCLUSIONS: It is common for DC-associated PF to occur later in life without significant hematological manifestations. Mutations in the genes encoding different components of the telomere maintenance pathway were associated with clinical phenotypes and prognosis. PF caused by DC should be kept in mind by clinicians in the differential diagnosis of patients with unexplained PF and should be excluded before diagnostic surgical lung biopsy is undertaken or empirical immunosuppression therapy is prescribed.


Subject(s)
Dyskeratosis Congenita/diagnosis , Idiopathic Pulmonary Fibrosis/diagnosis , Cell Cycle Proteins/genetics , DNA Helicases/genetics , Dyskeratosis Congenita/genetics , Dyskeratosis Congenita/pathology , Fatal Outcome , Humans , Idiopathic Pulmonary Fibrosis/genetics , Idiopathic Pulmonary Fibrosis/pathology , Male , Nuclear Proteins/genetics , Telomere-Binding Proteins/genetics , Young Adult
20.
J Pak Med Assoc ; 71(3): 1007-1010, 2021 Mar.
Article in English | MEDLINE | ID: mdl-34057965

ABSTRACT

Dyskeratosis congenita is a very rare inherited haematological disorder characterised by a classical clinical triad of leukoplakia, skin pigmentation and dystrophied nails. Here is a case of a young patient who presented with brittle nails, lacy hyperpigmentation of the skin and leukoplakia along with pancytopenia. Haematopoietic stem cell transplantation is the only cure for this disease but due to financial constraints of the family it was not possible. The patient was placed on androgen therapy and showed favourable response but later was lost to follow-up.


Subject(s)
Dyskeratosis Congenita , Hematopoietic Stem Cell Transplantation , Nail Diseases , Dyskeratosis Congenita/complications , Dyskeratosis Congenita/diagnosis , Dyskeratosis Congenita/therapy , Humans , Rare Diseases , Skin
SELECTION OF CITATIONS
SEARCH DETAIL
...